0001209191-20-025987.txt : 20200428 0001209191-20-025987.hdr.sgml : 20200428 20200428171058 ACCESSION NUMBER: 0001209191-20-025987 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200428 FILED AS OF DATE: 20200428 DATE AS OF CHANGE: 20200428 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Svennilson Peter CENTRAL INDEX KEY: 0001606074 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39269 FILM NUMBER: 20826080 MAIL ADDRESS: STREET 1: 1700 OWENS STREET STREET 2: SUITE 500 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Oric Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001796280 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 471787157 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 240 E. GRAND AVE. STREET 2: 2ND FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (650) 388-5600 MAIL ADDRESS: STREET 1: 240 E. GRAND AVE. STREET 2: 2ND FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-04-28 0 0001796280 Oric Pharmaceuticals, Inc. ORIC 0001606074 Svennilson Peter 1700 OWENS STREET, SUITE 500 SAN FRANCISCO CA 94158 1 0 1 0 Common Stock 2020-04-28 4 C 0 3500000 A 3575000 I See footnote Common Stock 2020-04-28 4 C 0 625000 A 4200000 I See footnote Common Stock 2020-04-28 4 C 0 416666 A 4616666 I See footnote Common Stock 2020-04-28 4 C 0 151515 A 4768181 I See footnote Series A Preferred Stock 2020-04-28 4 C 0 3500000 0.00 D Common Stock 3500000 0 I See footnote Series B Preferred Stock 2020-04-28 4 C 0 625000 0.00 D Common Stock 625000 0 I See footnote Series C Preferred Stock 2020-04-28 4 C 0 416666 0.00 D Common Stock 416666 0 I See footnote Series D Preferred Stock 2020-04-28 4 C 0 151515 0.00 D Common Stock 151515 0 I See footnote Each of the Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date. The shares are held of record by The Column Group II, LP ("TCG II LP"). The Column Group II GP, LP ("TCG II GP") is the general partner of TCG II LP. The Reporting Person is a Managing Partner of TCG II GP and may be deemed to share voting and investment power with respect to the shares reported herein. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein, if any. /s/ Dominic Piscitelli, attorney-in-fact 2020-04-28